Immuron (IMRN) Other Non-Current Liabilities (2017 - 2025)
Immuron (IMRN) posted quarterly Other Non-Current Liabilities of $718.55 for Q3 2025, down 45.95% year-over-year from $1329.4 in Q3 2024, and down 98.44% quarter-over-quarter from $46018.3 in Q2 2025.
Immuron (IMRN) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Immuron's Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $718.55 for Q3 2025.
- In Q3 2025, Other Non-Current Liabilities fell 45.95% year-over-year to $718.55; the TTM figure through Sep 2025 stood at $718.55 (down 45.95% YoY), while the FY2025 annual figure was $718.55, down 45.95% from the prior year.
- Other Non-Current Liabilities for Q3 2025 stood at $718.55, down from $46018.3 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $125641.3 in Q2 2022, with the low at $718.55 in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $60448.5 (2024), against an average of $58597.7.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities surged 8066.27% in 2022, then plunged 99.26% in 2023.
- Immuron's Other Non-Current Liabilities stood at $1411.3 in 2021, then surged by 8066.27% to $115248.9 in 2022, then slumped by 99.26% to $848.08 in 2023, then soared by 7027.65% to $60448.5 in 2024, then slumped by 98.81% to $718.55 in 2025.
- Business Quant data shows IMRN's Other Non-Current Liabilities at $718.55 in Q3 2025, $46018.3 in Q2 2025, and $60448.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 718.55 |
| Jun 30, 2025 | 46,018.33 |
| Dec 31, 2024 | 60,448.48 |
| Sep 9, 2024 | 1,329.41 |
| Jun 30, 2024 | 87,611.37 |
| Dec 31, 2023 | 848.08 |
| Sep 28, 2023 | 98,535.00 |
| Aug 30, 2023 | 1,503.25 |
| Jun 30, 2023 | 100,471.28 |
| Dec 31, 2022 | 115,248.85 |
| Aug 31, 2022 | 121,984.82 |
| Jun 30, 2022 | 125,641.34 |
| Dec 31, 2021 | 1,411.28 |
| Sep 1, 2020 | 18,929.00 |
| Jun 30, 2020 | 12,406.46 |
| Dec 31, 2019 | 189.29 |
| Dec 31, 2017 | -914,807.89 |